A Phase 2 interventional study of Efinopegdutide 20 mg/mL and Semaglutide 1.34 mg/mL in Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis, sponsored by Merck Sharp & Dohme LLC. Completed at 69 sites in 16 countries. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2023-11-15.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies in Non-alcoholic Fatty Liver Disease by Merck & Co., Inc — none open to participants now, none under way, none of them phase 3. Non-alcoholic Fatty Liver Disease · Merck & Co., Inc.
Among the 11 studies in Non-alcoholic Fatty Liver Disease by Merck & Co., Inc, this one is the 4th largest by enrollment of the 10 interventional ones that give a count, is one of 2 that started in 2021, is one of 7 in phase 2, and was the 6th registered.
1,617 studies on the registry are indexed under Non-alcoholic Fatty Liver Disease; 322 are open to participants now.
Browse Non-alcoholic Fatty Liver Disease studies →None of the 11 studies in Non-alcoholic Fatty Liver Disease by Merck & Co., Inc is open now. The open studies under Non-alcoholic Fatty Liver Disease, anywhere →
Of the 219 Non-alcoholic Fatty Liver Disease studies recruiting now, 66 (30%) set no upper age limit and 124 (57%) stop at 75 or younger; 27 take children under 18; 55 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
First in 2010; this study’s year is marked. 2 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 145 is above the median of 60 across 1,176 interventional studies indexed under Non-alcoholic Fatty Liver Disease.
Median enrollment 113 across the 10 interventional studies, 10 across the 1 observational. Of the 11 that completed or were terminated, 8 (73%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Merck Sharp & Dohme LLC, one of the names counted as Merck & Co., Inc. Under that name alone:
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 11 studies in Non-alcoholic Fatty Liver Disease by Merck & Co., Inc, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The principal goal of this study is to determine the efficacy of efinopegdutide in liver fat reduction in participants with NAFLD. The primary hypotheses are that efinopegdutide is superior to semaglutide, or that efinopegdutide is superior to semaglutide by at least 10% with respect to mean relative reduction from baseline in liver fat content (LFC) after 24 weeks.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Efinopegdutide 20 mg/mL administered by injection once weekly for 24 weeks in a dose-escalation regimen: 2.4 mg from day 1 to week 3, 5.0 mg from week 4 to 7, and 10.0 mg from week 8 to 24.
Drug: Efinopegdutide 20 mg/mL
Semaglutide 1.34 mg/mL administered by injection once weekly for 24 weeks in a dose-escalation regimen: 0.25 mg from day 1 to week 3, 0.5 mg from week 4 to 7, and 1.0 mg from week 8 to 24.
Drug: Semaglutide 1.34 mg/mL
Drug page: Efinopegdutide
Subcutaneous injection in a dose-escalation administration of 2.4 mg, 5.0 mg, and 10.0 mg
Also known as: MK-6024, HM12525A, JNJ-64565111
Drug page: Semaglutide
Subcutaneous injection in a dose-escalation administration of 0.25 mg, 0.5 mg, and 1.0 mg
Also known as: Ozempic®
Mean Relative Reduction From Baseline in Liver Fat Content (LFC) Measured by Magnetic Resonance Imaging-Estimated Proton Density Fat Fraction (MRI-PDFF), Evaluated by Blinded Independent Central Review (BICR) After 24 Weeks
LFC was measured with liver images taken by MRI-PDFF and analyzed by BICR. Relative Reduction from Baseline to Week 24 = (Baseline - Week 24) / Baseline x 100%. Mean relative reduction from baseline in liver fat content is presented.
Time frame: Baseline and up to ~24 Weeks
Percentage of Participants Who Experienced an Adverse Event (AE)
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The percentage of participants who experienced an adverse event is presented.
Time frame: Up to ~29 weeks
Percentage of Participants Who Discontinued Study Intervention Due to an AE
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The percentage of participants who discontinued study intervention due to adverse event is presented.
Time frame: Up to ~24 weeks
Mean Absolute Reduction From Baseline in LFC Measured by MRI-PDFF (Evaluated by BICR) After 24 Weeks
LFC was measured by liver images taken by MRI-PDFF and analyzed by BICR. The absolute reduction from baseline to Week 24 = Baseline - Week 24. The mean absolute reduction from baseline in LFC after 24 weeks of treatment is presented.
Time frame: Baseline and up to ~24 Weeks
Mean Percent Change From Baseline in Body Weight After 24 Weeks
Body weight in kilograms was measured using a standardized, digital scale. The mean percent change from baseline in body weight after 24 weeks is presented.
Time frame: Baseline and up to ~24 weeks
Mean Percent Change From Baseline in Total Cholesterol After 24 Weeks
Fasting blood samples were collected at baseline and after 24 weeks of treatment to assess mean percent change in total cholesterol. The mean percent change in total cholesterol is presented.
Time frame: Baseline and up to ~24 weeks
Mean Percent Change From Baseline in Non-High Density Lipoprotein-Cholesterol (Non-HDL-C) After 24 Weeks
Fasting blood samples were collected at baseline and after 24 weeks of treatment to assess mean percent change in non-HDL-C. The mean percent change in non-HDL-C is presented.
Time frame: Baseline and up to ~24 weeks
Mean Percent Change From Baseline in High Density Lipoprotein-Cholesterol (HDL-C) After 24 Weeks
Fasting blood samples were collected at baseline and after 24 weeks of treatment to assess mean percent change in HDL-C. Mean percent change in HDL-C is presented.
Time frame: Baseline and up to ~24 weeks
Mean Percent Change From Baseline in Low Density Lipoprotein-Cholesterol (LDL-C) After 24 Weeks
Fasting blood samples were collected at baseline and after 24 weeks of treatment to assess mean percent change in LDL-C. The mean percent change in LDL-C is presented.
Time frame: Baseline and up to ~24 weeks
Mean Percent Change From Baseline in Triglycerides (TG) After 24 Weeks
Fasting blood samples were collected at baseline and after 24 weeks of treatment to assess mean percent change in triglycerides. The mean percent change in triglycerides is presented.
Time frame: Baseline and up to ~24 weeks
Mean Percent Change From Baseline in Apolipoprotein B (apoB) After 24 Weeks
Fasting blood samples were collected at baseline and after 24 weeks of treatment to assess mean percent change in apoB. The mean percent change in apoB is presented.
Time frame: Baseline and up to ~24 weeks
This study was conducted at 51 clinical sites in 16 countries.
| Milestone | Efinopegdutide | Semaglutide |
|---|---|---|
| Started | 72 | 73 |
| Completed | 64 | 71 |
| Not completed | 8 | 2 |
| Withdrew: Lost to follow-up | 1 | 1 |
| Withdrew: Physician decision | 1 | 0 |
| Withdrew: Withdrawal by subject | 6 | 1 |
LFC was measured with liver images taken by MRI-PDFF and analyzed by BICR. Relative Reduction from Baseline to Week 24 = (Baseline - Week 24) / Baseline x 100%. Mean relative reduction from baseline in liver fat content is presented.
| Percent Reduction | Efinopegdutide | Semaglutide |
|---|---|---|
| Mean Relative Reduction From Baseline in Liver Fat Content (LFC) Measured by Magnetic Resonance Imaging-Estimated Proton Density Fat Fraction (MRI-PDFF), Evaluated by Blinded Independent Central Review (BICR) After 24 Weeks | 72.7 (66.8 to 78.7) | 42.3 (36.5 to 48.1) |
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The percentage of participants who experienced an adverse event is presented.
| Percentage of Participants | Efinopegdutide | Semaglutide |
|---|---|---|
| Percentage of Participants Who Experienced an Adverse Event (AE) | 88.9 | 72.6 |
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The percentage of participants who discontinued study intervention due to adverse event is presented.
| Percentage of Participants | Efinopegdutide | Semaglutide |
|---|---|---|
| Percentage of Participants Who Discontinued Study Intervention Due to an AE | 5.6 | 0 |
LFC was measured by liver images taken by MRI-PDFF and analyzed by BICR. The absolute reduction from baseline to Week 24 = Baseline - Week 24. The mean absolute reduction from baseline in LFC after 24 weeks of treatment is presented.
| Percentage of liver fat | Efinopegdutide | Semaglutide |
|---|---|---|
| Mean Absolute Reduction From Baseline in LFC Measured by MRI-PDFF (Evaluated by BICR) After 24 Weeks | 14.9 (13.6 to 16.3) | 8.8 (7.5 to 10.1) |
Body weight in kilograms was measured using a standardized, digital scale. The mean percent change from baseline in body weight after 24 weeks is presented.
| Percent Change | Efinopegdutide | Semaglutide |
|---|---|---|
| Mean Percent Change From Baseline in Body Weight After 24 Weeks | -8.5 (-9.5 to -7.5) | -7.1 (-8.1 to -6.2) |
Fasting blood samples were collected at baseline and after 24 weeks of treatment to assess mean percent change in total cholesterol. The mean percent change in total cholesterol is presented.
| Percent Change | Efinopegdutide | Semaglutide |
|---|---|---|
| Mean Percent Change From Baseline in Total Cholesterol After 24 Weeks | -15.2 (-18.2 to -12.2) | -8.0 (-11.0 to -5.0) |
Fasting blood samples were collected at baseline and after 24 weeks of treatment to assess mean percent change in non-HDL-C. The mean percent change in non-HDL-C is presented.
| Percent Change | Efinopegdutide | Semaglutide |
|---|---|---|
| Mean Percent Change From Baseline in Non-High Density Lipoprotein-Cholesterol (Non-HDL-C) After 24 Weeks | -16.8 (-20.5 to -13.0) | -11.0 (-14.8 to -7.3) |
Fasting blood samples were collected at baseline and after 24 weeks of treatment to assess mean percent change in HDL-C. Mean percent change in HDL-C is presented.
| Percent Change | Efinopegdutide | Semaglutide |
|---|---|---|
| Mean Percent Change From Baseline in High Density Lipoprotein-Cholesterol (HDL-C) After 24 Weeks | -8.1 (-11.2 to -5.1) | 3.6 (0.6 to 6.6) |
Fasting blood samples were collected at baseline and after 24 weeks of treatment to assess mean percent change in LDL-C. The mean percent change in LDL-C is presented.
| Percent Change | Efinopegdutide | Semaglutide |
|---|---|---|
| Mean Percent Change From Baseline in Low Density Lipoprotein-Cholesterol (LDL-C) After 24 Weeks | -13.0 (-17.4 to -8.6) | -6.9 (-11.3 to -2.6) |
Fasting blood samples were collected at baseline and after 24 weeks of treatment to assess mean percent change in triglycerides. The mean percent change in triglycerides is presented.
| Percent Change | Efinopegdutide | Semaglutide |
|---|---|---|
| Mean Percent Change From Baseline in Triglycerides (TG) After 24 Weeks | -30.9 (-35.6 to -25.8) | -23.3 (-28.5 to -17.7) |
Fasting blood samples were collected at baseline and after 24 weeks of treatment to assess mean percent change in apoB. The mean percent change in apoB is presented.
| Percent Change | Efinopegdutide | Semaglutide |
|---|---|---|
| Mean Percent Change From Baseline in Apolipoprotein B (apoB) After 24 Weeks | -14.7 (-18.2 to -11.1) | -9.2 (-12.8 to -5.7) |
Collected over Death and adverse events up to ~29 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Efinopegdutide | 0/72 (0%) | 1/72 (1.4%) | 57/72 (79.2%) |
| Semaglutide | 0/73 (0%) | 1/73 (1.4%) | 44/73 (60.3%) |
| Event | Efinopegdutide | Semaglutide |
|---|---|---|
| Calculus urinaryRenal and urinary disorders | 1/72 | 0/73 |
| Spinal osteoarthritisMusculoskeletal and connective tissue disorders | 0/72 | 1/73 |
| Event | Efinopegdutide | Semaglutide |
|---|---|---|
| NauseaGastrointestinal disorders | 20/72 | 23/73 |
| DiarrhoeaGastrointestinal disorders | 12/72 | 13/73 |
| ConstipationGastrointestinal disorders | 12/72 | 4/73 |
| VomitingGastrointestinal disorders | 12/72 | 11/73 |
| Decreased appetiteMetabolism and nutrition disorders | 12/72 | 11/73 |
| COVID-19Infections and infestations | 8/72 | 10/73 |
| Abdominal painGastrointestinal disorders | 9/72 | 2/73 |
| Abdominal pain upperGastrointestinal disorders | 7/72 | 1/73 |
| DyspepsiaGastrointestinal disorders | 6/72 | 5/73 |
| Gastrooesophageal reflux diseaseGastrointestinal disorders | 6/72 | 5/73 |
| Age, Continuous(Years) | Efinopegdutide | Semaglutide | Total |
|---|---|---|---|
| Mean | 48.0 ± 11.0 | 50.7 ± 10.9 | 49.4 ± 11.0 |
| Sex: Female, Male(Participants) | Efinopegdutide | Semaglutide | Total |
|---|---|---|---|
| Female | 39 | 41 | 80 |
| Male | 33 | 32 | 65 |
| Ethnicity (NIH/OMB)(Participants) | Efinopegdutide | Semaglutide | Total |
|---|---|---|---|
| Hispanic or Latino | 25 | 26 | 51 |
| Not Hispanic or Latino | 46 | 47 | 93 |
| Unknown or Not Reported | 1 | 0 | 1 |
| Race (NIH/OMB)(Participants) | Efinopegdutide | Semaglutide | Total |
|---|---|---|---|
| American Indian or Alaska Native | 3 | 2 | 5 |
| Asian | 7 | 7 | 14 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 1 | 1 |
| White | 62 | 63 | 125 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Body Mass Index (BMI)(Kg/M^2) | Efinopegdutide | Semaglutide | Total |
|---|---|---|---|
| Mean | 35.2 ± 5.7 | 33.5 ± 5.0 | 34.3 ± 5.4 |
| Weight(kg) | Efinopegdutide | Semaglutide | Total |
|---|---|---|---|
| Mean | 100.2 ± 18.9 | 94.4 ± 18.9 | 97.3 ± 19.1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf
Data sharing details ↗ · engagezone.msd.com
Ran from Aug 2021 to primary completion in Oct 2022, 14 months.
Results were first posted in Nov 2023, 1 year after primary completion.
Of 132 industry-sponsored phase 2 interventional studies under Non-alcoholic Fatty Liver Disease, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 30. This study's 14 months is below that.
Counting every sponsor, half of 185 studies reached it within 26 months; a quarter within 16 and three quarters within 36.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Efinopegdutide
Non-alcoholic Fatty Liver Disease →